ZX 101A
Alternative Names: ZX-101ALatest Information Update: 14 Nov 2024
Price :
$50 *
At a glance
- Originator Nanjing Zenshine Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma
- No development reported Solid tumours
Most Recent Events
- 05 Jul 2024 Nanjing Zenshine Pharmaceuticals completes a phase-I/II clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in China (PO) (NCT05269940)
- 05 Jul 2024 Nanjing Zenshine Pharmaceuticals completes a phase-I/II clinical trials in Haematological malignancies (Second-line therapy or greater) in China (PO) (NCT05269940)
- 05 Jul 2024 Nanjing Zenshine Pharmaceuticals completes a phase-I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (PO) (NCT05269940)